Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05928936 · ClinicalTrials.gov registry record · Phase 2

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

A Phase 2 study of Chronic Kidney Disease, sponsored by Emory University.

Recruiting
Registry status
Phase 2
Development phase
156
Enrollment target
2
Study locations

NCT05928936: Recruiting Phase 2 study of Chronic Kidney Disease, sponsored by Emory University.

NCT05928936 is a Phase 2 study of Chronic Kidney Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 156 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05928936, a Phase 2 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 2
Development phase
156 participants
Enrollment target
2
Study locations

Study Summary

The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

Primary Outcome

Exercise capacity measured as VO2 peak during a maximal treadmill exercise test. Higher VO2 max indicates increased oxygen consumption and improved fitness.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Sodium Bicarbonate
  • BEHAVIORAL Exercise Training

Study Locations (2)

Georgia

  • Emory Clinic - Atlanta
  • Atlanta VA Medical Center - Decatur

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2022-11-11
Est. Completion 2028-06-01
Phase Phase 2
Emory University

1,208 total trials

What NCT05928936 shows while recruiting

NCT05928936 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05928936 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT05928936 about?

NCT05928936 is a clinical study titled "Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD". The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

What is the current status of trial NCT05928936?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2022-11-11. Estimated completion is 2028-06-01.

What conditions does trial NCT05928936 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT05928936?

The interventions under investigation include: Placebo (DRUG), Sodium Bicarbonate (DRUG), Exercise Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT05928936?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05928936 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05928936's enrollment target sits among peer trials

156 44th of 101 higher than 58 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03082755 · 156 participants · Phase 4

    Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

  • NCT04047628 · 156 participants · Phase 3

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

  • NCT04166877 · 156 participants · Phase 4

    Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

  • NCT04533464 · 156 participants · Phase 2

    MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05928936, the US trial registry maintained by the National Library of Medicine. NCT05928936 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.